Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2018 May 29. pii: 122301. doi: 10.1172/JCI122301. [Epub ahead of print] No abstract available.

2.

Oral Administration of Recombinant Saccharomyces boulardii Expressing Ovalbumin-CPE Fusion Protein Induces Antibody Response in Mice.

Bagherpour G, Ghasemi H, Zand B, Zarei N, Roohvand F, Ardakani EM, Azizi M, Khalaj V.

Front Microbiol. 2018 Apr 13;9:723. doi: 10.3389/fmicb.2018.00723. eCollection 2018.

3.

Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction.

Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemmerle M, Gharpure KM, Rupaimoole R, Previs RA, Wu SY, Pradeep S, Xu X, Han HD, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong STC, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, De Biasi M, Sood AK.

Cancer Res. 2018 Jun 15;78(12):3233-3242. doi: 10.1158/0008-5472.CAN-16-1701. Epub 2018 Apr 16.

PMID:
29661830
4.

SSRI use and clinical outcomes in epithelial ovarian cancer.

Christensen DK, Armaiz-Pena GN, Ramirez E, Matsuo K, Zimmerman B, Zand B, Shinn E, Goodheart MJ, Bender D, Thaker PH, Ahmed A, Penedo FJ, DeGeest K, Mendez L, Domann F, Sood AK, Lutgendorf SK.

Oncotarget. 2016 May 31;7(22):33179-91. doi: 10.18632/oncotarget.8891.

5.

FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.

Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK.

J Clin Invest. 2016 May 2;126(5):1885-96. doi: 10.1172/JCI85086. Epub 2016 Apr 11.

6.

Role of Increased n-acetylaspartate Levels in Cancer.

Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK.

J Natl Cancer Inst. 2016 Jan 26;108(6):djv426. doi: 10.1093/jnci/djv426.

7.

Erythropoietin Stimulates Tumor Growth via EphB4.

Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Peña GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK.

Cancer Cell. 2015 Nov 9;28(5):610-622. doi: 10.1016/j.ccell.2015.09.008. Epub 2015 Oct 17.

8.

Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis.

Nagaraja AS, Dorniak PL, Sadaoui NC, Kang Y, Lin T, Armaiz-Pena G, Wu SY, Rupaimoole R, Allen JK, Gharpure KM, Pradeep S, Zand B, Previs RA, Hansen JM, Ivan C, Rodriguez-Aguayo C, Yang P, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK.

Oncogene. 2016 May 5;35(18):2390-7. doi: 10.1038/onc.2015.302. Epub 2015 Aug 10.

9.

XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.

Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MS, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, Liu T, Shacham S, McCauley D, Hawke DH, Wiktorowicz JE, Coleman RL, Sood AK.

Clin Cancer Res. 2015 Jul 15;21(14):3286-97. doi: 10.1158/1078-0432.CCR-14-1953. Epub 2015 Apr 15.

10.

Differential platelet levels affect response to taxane-based therapy in ovarian cancer.

Bottsford-Miller J, Choi HJ, Dalton HJ, Stone RL, Cho MS, Haemmerle M, Nick AM, Pradeep S, Zand B, Previs RA, Pecot CV, Crane EK, Hu W, Lutgendorf SK, Afshar-Kharghan V, Sood AK.

Clin Cancer Res. 2015 Feb 1;21(3):602-10. doi: 10.1158/1078-0432.CCR-14-0870. Epub 2014 Dec 3.

11.

Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.

Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK.

Clin Cancer Res. 2015 Jan 15;21(2):448-59. doi: 10.1158/1078-0432.CCR-14-1578. Epub 2014 Nov 21.

12.

Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.

Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, Mangala LS, Taylor M, van den Beucken T, Koch E, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Wouters BG, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AK.

Nat Commun. 2014 Oct 29;5:5202. doi: 10.1038/ncomms6202.

13.

Therapeutic silencing of KRAS using systemically delivered siRNAs.

Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AK.

Mol Cancer Ther. 2014 Dec;13(12):2876-85. doi: 10.1158/1535-7163.MCT-14-0074. Epub 2014 Oct 3.

14.

Hematogenous metastasis of ovarian cancer: rethinking mode of spread.

Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK.

Cancer Cell. 2014 Jul 14;26(1):77-91. doi: 10.1016/j.ccr.2014.05.002.

15.

Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.

Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, Lutgendorf S, Sood AK.

Cancer Biol Ther. 2014 Jul;15(7):919-29. doi: 10.4161/cbt.28882. Epub 2014 Apr 23.

16.

Notch3 pathway alterations in ovarian cancer.

Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK.

Cancer Res. 2014 Jun 15;74(12):3282-93. doi: 10.1158/0008-5472.CAN-13-2066. Epub 2014 Apr 17.

17.

Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.

Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK.

Cell Rep. 2014 Apr 24;7(2):488-500. doi: 10.1016/j.celrep.2014.03.009. Epub 2014 Apr 3.

18.

Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.

Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, Lee JS, Ram P, Coleman RL, Sood AK.

Clin Cancer Res. 2014 May 15;20(10):2740-50. doi: 10.1158/1078-0432.CCR-13-2507. Epub 2014 Mar 14.

19.

Autocrine effects of tumor-derived complement.

Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, Lopez-Berestein G, Sood AK, Afshar-Kharghan V.

Cell Rep. 2014 Mar 27;6(6):1085-1095. doi: 10.1016/j.celrep.2014.02.014. Epub 2014 Mar 6.

20.

Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.

Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapprapasr D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Jennings NB, Huang L, Deavers MT, Broaddus R, Coleman RL, Sood AK.

Clin Cancer Res. 2014 Apr 1;20(7):1846-55. doi: 10.1158/1078-0432.CCR-13-2141. Epub 2014 Jan 31.

21.

Targeting SRC and tubulin in mucinous ovarian carcinoma.

Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer DG, Coleman RL, Frumovitz M, Sood AK.

Clin Cancer Res. 2013 Dec 1;19(23):6532-43. doi: 10.1158/1078-0432.CCR-13-1305. Epub 2013 Oct 7.

22.

Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.

Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AK.

J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95. doi: 10.1093/jnci/djt210. Epub 2013 Sep 23.

23.

Tumour angiogenesis regulation by the miR-200 family.

Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AK.

Nat Commun. 2013;4:2427. doi: 10.1038/ncomms3427.

24.

Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.

Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GA.

Cancer Discov. 2013 Nov;3(11):1302-15. doi: 10.1158/2159-8290.CD-13-0159. Epub 2013 Sep 3.

25.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2013 May;123(5):2119-30. doi: 10.1172/JCI65425. Epub 2013 Apr 15.

26.

Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer.

Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK.

Gynecol Oncol. 2013 Mar;128(3):506-11. doi: 10.1016/j.ygyno.2012.11.029. Epub 2012 Nov 28.

27.

Platelets increase the proliferation of ovarian cancer cells.

Cho MS, Bottsford-Miller J, Vasquez HG, Stone R, Zand B, Kroll MH, Sood AK, Afshar-Kharghan V.

Blood. 2012 Dec 6;120(24):4869-72. doi: 10.1182/blood-2012-06-438598. Epub 2012 Sep 10.

28.

Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.

Lee SJ, Ghosh SC, Han HD, Stone RL, Bottsford-Miller J, Shen DY, Auzenne EJ, Lopez-Araujo A, Lu C, Nishimura M, Pecot CV, Zand B, Thanapprapasr D, Jennings NB, Kang Y, Huang J, Hu W, Klostergaard J, Sood AK.

Clin Cancer Res. 2012 Aug 1;18(15):4114-21. doi: 10.1158/1078-0432.CCR-11-3250. Epub 2012 Jun 12.

29.

Risk factors for prolonged hospitalization after gynecologic laparoscopic surgery.

Zand B, Frumovitz M, Jofre MF, Nick AM, Dos Reis R, Munsell MF, Sangi-Haghpeykar H, Levenback C, Soliman PT, Schmeler KM, Ramirez PT.

Gynecol Oncol. 2012 Sep;126(3):428-31. doi: 10.1016/j.ygyno.2012.05.037. Epub 2012 Jun 2.

30.

Targeting angiogenesis in gynecologic cancers.

Zand B, Coleman RL, Sood AK.

Hematol Oncol Clin North Am. 2012 Jun;26(3):543-63, viii. doi: 10.1016/j.hoc.2012.01.009. Review.

31.

Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer.

Zand B, Euscher ED, Soliman PT, Schmeler KM, Coleman RL, Frumovitz M, Jhingran A, Ramondetta LM, Ramirez PT.

Gynecol Oncol. 2010 Dec;119(3):422-5. doi: 10.1016/j.ygyno.2010.08.012. Epub 2010 Sep 15.

32.

Effect of plant density and mixing ratio on crop yield in sweet corn/mungbean intercropping.

Sarlak S, Aghaalikhani M, Zand B.

Pak J Biol Sci. 2008 Sep 1;11(17):2128-33.

PMID:
19266927
33.

Transfection and functional expression of CYP4A1 and CYP4A2 using bicistronic vectors in vascular cells and tissues.

Wang JS, Zhang F, Jiang M, Wang MH, Zand BA, Abraham NG, Nasjletti A, Laniado-Schwartzman M.

J Pharmacol Exp Ther. 2004 Dec;311(3):913-20. Epub 2004 Jul 21.

34.

Transfection of CYP4A1 cDNA decreases diameter and increases responsiveness of gracilis muscle arterioles to constrictor stimuli.

Zhang F, Wang MH, Wang JS, Zand B, Gopal VR, Falck JR, Laniado-Schwartzman M, Nasjletti A.

Am J Physiol Heart Circ Physiol. 2004 Sep;287(3):H1089-95. Epub 2004 May 6.

35.

Regulation of renal CYP4A expression and 20-HETE synthesis by nitric oxide in pregnant rats.

Wang MH, Wang J, Chang HH, Zand BA, Jiang M, Nasjletti A, Laniado-Schwartzman M.

Am J Physiol Renal Physiol. 2003 Aug;285(2):F295-302. Epub 2003 Apr 8.

36.

Renal 20-hydroxyeicosatetraenoic acid synthesis during pregnancy.

Wang MH, Zand BA, Nasjletti A, Laniado-Schwartzman M.

Am J Physiol Regul Integr Comp Physiol. 2002 Feb;282(2):R383-9.

37.

Heme oxygenase isoform-specific expression and distribution in the rat kidney.

da Silva JL, Zand BA, Yang LM, Sabaawy HE, Lianos E, Abraham NG.

Kidney Int. 2001 Apr;59(4):1448-57.

38.

CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR.

Wang MH, Zhang F, Marji J, Zand BA, Nasjletti A, Laniado-Schwartzman M.

Am J Physiol Regul Integr Comp Physiol. 2001 Jan;280(1):R255-61.

39.

Adenoviral vector-mediated transfer of human heme oxygenase in rats decreases renal heme-dependent arachidonic acid epoxygenase activity.

Abraham NG, Jiang S, Yang L, Zand BA, Laniado-Schwartzman M, Marji J, Drummond GS, Kappas A.

J Pharmacol Exp Ther. 2000 May;293(2):494-500.

40.

Contribution of cytochrome P-450 4A1 and 4A2 to vascular 20-hydroxyeicosatetraenoic acid synthesis in rat kidneys.

Wang MH, Guan H, Nguyen X, Zand BA, Nasjletti A, Laniado-Schwartzman M.

Am J Physiol. 1999 Feb;276(2 Pt 2):F246-53.

PMID:
9950955
41.

Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors.

Wang MH, Brand-Schieber E, Zand BA, Nguyen X, Falck JR, Balu N, Schwartzman ML.

J Pharmacol Exp Ther. 1998 Mar;284(3):966-73.

Supplemental Content

Support Center